MBX Biosciences Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended June 30, 2026OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from _________________ to _________________Commission File Number: 001-42272 MBX Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware(State or other jurisdiction ofincorporation or organization) 84-1882872(I.R.S. EmployerIdentification No.) 11711 N. Meridian Street, Suite 300Carmel, Indiana(Address of principal executive offices) (317) 659-0200 Registrant’s telephone number, including area code Securities registered pursuant to Section 12(b) of the Act: Title of each classTradingSymbol(s)Name of each exchange on which registeredCommon Stock, par value $0.0001 per shareMBXThe Nasdaq Global Select Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒Emerging growth company☒ Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of August 3, 2026, the registrant had 48,160,096 shares of common stock, $0.0001 par value per share, outstanding. Table of Contents PART I.FINANCIAL INFORMATION Item 1.Financial Statements (Unaudited)Condensed Balance SheetsCondensed Statements of Operations and Comprehensive LossCondensed Statements of Stockholders’ Equity (Deficit) and Convertible Preferred StockCondensed Statements of Cash FlowsNotes to Unaudited Condensed Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and Procedures PART II.OTHER INFORMATION Item 1.Legal Proceedings30Item 1A.Risk Factors30Item 2.Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities30Item 3.Defaults Upon Senior Securities30Item 4.Mine Safety Disclosures30Item 5.Other Information30Item 6.Exhibits31Signatures32 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this "Quarterly Report") contains forward looking statements, including the sectionsentitled "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors". Thesesections contain express or implied forward-looking statements that are based on our management's belief and assumptions and oninformation currently available to our management. Although we believe that the expectations reflected in these forward-lookingstatements are reasonable, these statements relate to future events or our future operational or financial performance, and involveknown and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to bematerially different from any future results, performance or achievements expressed or implied by these forward-lookingstatements. Forward-looking statements in this Quarterly Report include, but are not limited to, statements about: •the initiation, timing, progress and results of our current and future research and development programs, preclinicalstudies and clinical trials; •our ability to successfully complete our clinical trials;•our ability to finalize the design or formulation of any product candidate;•the ability of our platform to optimize pharmacokinetic and/or pharmacologic properties;•our ability to advance any product candidates that we may identify and successfully complete any clinical studies,including the manufacture of any such product candidates;•our ability to quickly leverage programs within ou